Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Klisyri (tirbanibulin) is indicated for the topical treatment of actinic keratosis of the face or scalp.
• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Tirbanibulin 1% ointment demonstrated an odds ratio (OR) of 11.1 (95% credible interval: 6.2-20.9) for achieving complete clearance of actinic keratosis (AK) on the face and scalp when compared to a topical placebo or vehicle.
• When compared to other treatments, Tirbanibulin showed varying odds ratios: 13.4 (6.2-30.3) against cryosurgery, 2.9 (1.9-4.3) against Diclofenac 3%, 7.6 (4.6-13.5) against Fluorouracil 0.5% + salicylic acid, and 12.5 (8.1-19.9) against Ingenol mebutate 0.015%. Higher ORs were noted against Fluorouracil 4% (30.3, 9.1-144.7), Fluorouracil 5% (35.0, 10.2-164.4), and certain photodynamic therapies.
• Tirbanibulin was noted to have a favorable safety profile, with no serious or systemic adverse events reported, and a more favorable tolerability profile compared to topical 5-FU and imiquimod.
• Application-site adverse events and local skin reactions were less frequent with newer agents like tirbanibulin and ingenol mebutate, indicating minimal safety concerns.
• There is no population types or subgroups information available in the reviewed studies.